1. Home
  2. SWAG vs BRNS Comparison

SWAG vs BRNS Comparison

Compare SWAG & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stran & Company Inc.

SWAG

Stran & Company Inc.

HOLD

Current Price

$1.66

Market Cap

28.2M

ML Signal

HOLD

Logo Barinthus Biotherapeutics plc

BRNS

Barinthus Biotherapeutics plc

HOLD

Current Price

$0.69

Market Cap

24.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWAG
BRNS
Founded
1994
2016
Country
United States
United States
Employees
156
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.2M
24.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SWAG
BRNS
Price
$1.66
$0.69
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
37.9K
16.9K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.51
52 Week High
$3.50
$2.91

Technical Indicators

Market Signals
Indicator
SWAG
BRNS
Relative Strength Index (RSI) 51.07 54.61
Support Level $1.59 $0.54
Resistance Level $1.84 $0.76
Average True Range (ATR) 0.10 0.05
MACD 0.00 0.00
Stochastic Oscillator 50.00 41.83

Price Performance

Historical Comparison
SWAG
BRNS

About SWAG Stran & Company Inc.

Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, it offers its clients custom sourcing capabilities, which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, event assets, order and inventory management, and designing and hosting online retail pop-up shops. The company's segment consists of the Stran segment and the SLS segment. The company generates the majority of its revenue from the Stran segment.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Share on Social Networks: